BeiGene, Ltd. — Q1 2022 Form 10-Q
Filing identity: The supplied filing is for BeiGene, Ltd., not a registrant identified as BeOne Medicines Ltd. It reports the unaudited three months ended March 31, 2022; comparative income and cash-flow figures are for Q1 2021. Amounts below are U.S. dollars unless noted.
Business context
BeiGene is a global commercial-stage biotechnology company focused on oncology. It sells internally developed medicines, including BRUKINSA, tislelizumab and pamiparib, and distributes licensed medicines, particularly in China. It also collaborates with Novartis and Amgen. The company reported more than 8,300 employees and over 90 ongoing or planned clinical trials.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Product revenue, net | $261.6 million | $106.1 million; up 146.5% |
| Collaboration revenue | $45.1 million | $499.8 million; down 91.0% |
| Total revenue | $306.6 million | $605.9 million; down 49.4% |
| Cost of sales; product gross margin | $65.2 million; 75.1% | $32.7 million; 69.2% |
| Research and development expense | $389.9 million | $320.7 million; up 21.6% |
| Selling, general and administrative expense | $294.6 million | $182.1 million; up 61.8% |
| Operating loss | $443.3 million | Operating income of $70.2 million |
| Net loss | $434.3 million | Net income of $66.5 million |
| Operating cash flow | Use of $236.6 million | Provided $125.1 million |
Product sales growth was led by BRUKINSA ($104.3 million, up 372.3%) and tislelizumab ($87.6 million, up 79.3%). Q1 2022 also included China sales of BLINCYTO, KYPROLIS and POBEVCY. The prior-year period included $484.6 million of tislelizumab license revenue recognized after delivery of the Novartis license; this largely explains the year-over-year total revenue decline.
Gross margin improved with a higher mix of BRUKINSA and tislelizumab and the absence of a $24.2 million prior-year adjustment related to NRDL price reductions. The company noted that lower NRDL prices partly offset these benefits. Q1 2022 included $65.6 million of share-based compensation.
At March 31, 2022, cash, cash equivalents and restricted cash were $4.354 billion; short-term investments were $1.898 billion; and total debt was $609.0 million, including $407.4 million current debt and $201.6 million long-term bank loans. Current assets were $6.948 billion and current liabilities $1.376 billion. Total assets were $8.021 billion and equity $5.886 billion. Accumulated deficit was $5.400 billion. Cash, cash equivalents and restricted cash declined $28.4 million during the quarter. Management stated that cash, cash equivalents and short-term investments were expected to fund operating expenses and capital requirements for at least 12 months after issuance of the financial statements.
Material changes and notable items
- Product revenue more than doubled year over year, while collaboration revenue fell sharply because Q1 2021 recognized most of the $650 million Novartis tislelizumab upfront payment as license revenue.
- R&D and SG&A spending increased as the company expanded clinical development, internal research and global commercial operations. Internal R&D expense rose 49.5% to $241.6 million.
- Q1 2022 collaboration revenue included $26.2 million recognized for Novartis’s ociperlimab access and know-how performance obligation, $13.4 million of R&D services and $5.4 million from clinical supply sales. The company received a $300 million Novartis upfront payment in January 2022; potential option, milestone and royalty proceeds remain contingent.
- Investing cash flow was $210.4 million, including $331.0 million from investment maturities and sales, offset by $45.1 million of capital expenditures and a $75.0 million in-process R&D purchase. Financing used $11.3 million net, including $73.1 million of short-term loan repayments.
- Contractual and other obligations totaled $1.873 billion, including $746.8 million remaining Amgen co-development funding, $239.4 million capital commitments and $122.5 million purchase commitments. Potential future milestone payments on in-licensed technology totaled $5.7 billion; achievement and timing are uncertain and these were not recorded as balance-sheet liabilities.
- PRC subsidiary net assets subject to restrictions on transfer were $2.692 billion, versus $799.6 million at year-end 2021. The filing cites statutory reserve, foreign-exchange and other transfer constraints.
Outlook, risks and contingencies
BeiGene gave no quantitative revenue or earnings guidance and stated that results are not necessarily indicative of full-year performance. Management expects R&D costs to increase as programs advance and SG&A to rise to support commercialization and potential launches. The company expects continued net losses for the foreseeable future and does not expect to pay dividends in the foreseeable future. It may require additional financing to complete its development and investment plans, despite its stated 12-month liquidity outlook.
Key risks include clinical-trial outcomes and regulatory approvals; competition and market acceptance; pricing, reimbursement and NRDL reductions; reliance on third-party manufacturers and distributors; rapid organizational growth and rising expenses; COVID-19-related disruption; China-U.S. relations, currency conversion and data regulation; and intellectual-property protection. The filing also discusses HFCAA and possible U.S. trading restrictions: the prior auditor was subject to PCAOB inspection restrictions and the company had been identified under the HFCAA. BeiGene appointed Ernst & Young LLP in Boston as principal auditor for 2022 and expected this to address inspection requirements, but said success was not assured.
In a pending ICC arbitration, BeiGene alleges BMS-Celgene breached its ABRAXANE supply and license agreement and disputes BMS-Celgene’s purported termination. BMS-Celgene counterclaimed for approximately $30 million in recall-related costs; a hearing was scheduled for June 2022. The company said it was not party to other legal proceedings expected to have a material adverse effect. Management reported disclosure controls effective at a reasonable assurance level and completed additional control processes during the quarter.
After quarter-end, the company reported conditional China approval of BLINCYTO for pediatric patients with relapsed or refractory ALL, China approval of tislelizumab for certain esophageal cancer patients, and positive or review-related clinical and regulatory developments for tislelizumab and BRUKINSA. These are developments disclosed in the filing, not Q1 revenue results.
Important facts for investors to verify
- Confirm the issuer identity: this filing is BeiGene, Ltd.; reconcile that with the requested company name.
- Track product-sales growth, particularly BRUKINSA and tislelizumab, against price reductions, reimbursement access and rising commercial costs.
- Assess cash burn, the pace of capital spending, debt maturities and whether the stated 12-month funding outlook remains valid.
- Monitor clinical milestones, regulatory decisions and Novartis’s ociperlimab option; contingent payments are not assured revenue.
- Review the ABRAXANE arbitration, including the approximately $30 million counterclaim and the status of the disputed termination.
- Follow PCAOB inspection and HFCAA developments and confirm whether the new U.S.-based auditor resolves the identified listing risk.
- Evaluate the company’s substantial contractual commitments, possible in-licensing milestones and restrictions on transferring PRC subsidiary assets.